Trial Information
Drug Use Investigation of Zevalin
Inclusion Criteria:
Patients who received Zevalin for relapsed or refractory:
- CD20+
- low grade B-cell non-Hodgkin's lymphoma
- Mantle cell lymphoma
Exclusion Criteria:
- Patients who are contraindicated based on the product label
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Incidence of adverse drug reactions in subjects who received Zevalin
Outcome Time Frame:
After In-111 Zevalin administration, up to 13 weeks
Safety Issue:
Yes
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
15042
NCT ID:
NCT01448928
Start Date:
September 2008
Completion Date:
January 2018
Related Keywords:
- Non-Hodgkin's Lymphoma (NHL)
- Zevalin
- CD20+
- Non-Hodgkin's Lymphoma
- Mantle Cell Lymphoma
- Lymphoma
- Lymphoma, Non-Hodgkin